Lume Health has secured fresh funding to advance a wrist-worn device designed to track cortisol and decode circadian health. According to reports, the company has now raised $2.5 million, built a waitlist of more than 5,200 people, and is using the capital to support pre-launch development and scientific validation.
That matters because Lume is targeting…
Danone has agreed to acquire Huel in a deal valued at approximately $1bn, bringing one of the fastest-growing meal replacement brands into a global food portfolio.
Huel, founded in the UK, has built a direct-to-consumer business around powdered and ready-to-drink meals designed to provide complete nutrition. The company has scaled rapidly, reaching hundreds of millions…
Perplexity AI is expanding into healthcare, positioning its AI-powered search platform as a tool for delivering real-time medical information and guidance.
The company has built its product around an answer engine that retrieves, synthesises and cites information in response to user queries. Applying that model to healthcare introduces a higher-stakes use case, where accuracy, transparency…
Christian Larsen does not hedge when the conversation turns to AI.
If a superintelligent AI “species” emerges, one that is faster, more capable and operating at a fundamentally different level of capacity, he believes the outcome is already decided. “There’s no question that they will have the upper hand,” he says. Not in ten years.…
Mave Health has raised $2.1 million to develop a wearable headset designed to improve attention, mood and stress regulation through non-invasive brain stimulation.
The company is preparing to launch the device in 2026, targeting consumers looking for tools to manage cognitive performance and emotional state in real time.
The funding reflects growing interest in neurotechnology…
Eli Lilly is progressing its experimental obesity and type 2 diabetes drug retatrutide into Phase 3 trials, following late-stage data showing significant weight loss and metabolic improvements.
Retatrutide belongs to a new class of drugs known as triple agonists, targeting three key metabolic pathways simultaneously. In earlier trials, the drug demonstrated weight loss outcomes exceeding…
London-based Solo60 has raised £2.5 million ($3.3 million) to accelerate expansion across the UK and support longer-term international growth. The company lets consumers, personal trainers and influencers book private training spaces by the hour through a mobile app, rather than joining a conventional shared gym.
That matters because Solo60 is not simply opening smaller gyms.…
F45 is entering the competitive fitness space with the launch of Peak500, a hybrid fitness competition developed in partnership with Red Bull.
The format introduces a standardised race-style event built around functional training, combining elements of strength, conditioning, and endurance into a repeatable competition structure.
Participants complete a series of timed workout stations designed to…
Peloton is expanding its commercial strategy by growing its Precor division, supplying connected fitness equipment directly to gyms, hotels, and multi-family residential spaces.
Precor, which Peloton acquired for $420 million in 2020, has traditionally operated as a commercial equipment manufacturer. The current move involves integrating Peloton’s digital content and connected software into that installed base.…
Xenom has raised $15 million and calls itself the “decathlon of fitness”. That’s the headline but it’s not the most interesting thing about the latest addition to the competitive fitness calendar.
Xenom is a new global fitness competition designed to test all-round fitness across a standardised format. What really stands out is how Xenom founder…



